Generic drugmaker Teva Pharmaceutical Industries Ltd. has agreed to pay more than $283 million to resolve criminal charges and fines over bribes to government officials in Russia, Ukraine and Mexico, in violation of the Foreign Corrupt Practices Act, the U.S. Department of Justice announced Thursday.
Teva also agreed to pay $236 million in disgorgement to the U.S. Securities and Exchange Commission in related proceedings. The combined total amount of U.S. criminal and regulatory penalties to be paid by Teva is nearly $520 million, which the DOJ said was the largest criminal fine imposed against a pharmaceutical company for violations of the FCPA.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
